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This document reﬂects the key points of a consensus meeting of the Heart Failure
Association of European Society of Cardiology (ESC) held to provide an overview the
role of physiological monitoring in the complex multimorbid heart failure (HF) pa-
tient. This article reviews assessments of the functional ability of patients with HF.
The gold standard measurement of cardiovascular functional capacity is peak oxygen
consumption obtained from a cardiopulmonary exercise test. The 6-min walk test
provides an indirect measure of cardiovascular functional capacity. Muscular func-
tional capacity is assessed using either a 1repetition maximum test of the upper
and lower body or other methods, such as handgrip measurement. The short physical
performance battery may provide a helpful, indirect indication of muscular func-
tional capacity.
Introduction
One of the hallmark features of heart failure (HF) is exer-
cise intolerance, which is accompanied by symptoms of fa-
tigue and shortness of breath.1,2 As the disease progresses,
patients experience a downward spiral as these symptoms
typically result in reduced physical activity, which leads to
progressively worsening exercise intolerance.3,4 Typically,
patients with HF are faced with what can be termed a func-
tional disability.5–7 Often, their reduced functional abilities
restrict or may even prevent them from performing occu-
pational tasks, which may result in loss of work.8
Additionally, it is well known that HF patients experience
impairment in the ability to carry out activities of daily liv-
ing and suffer from an impaired quality of life.9–11
Cardiopulmonary exercise testing
The gold standard method for assessing cardiovascular
functional capacity is measurement of oxygen consumption
(VO2) during a maximal exercise test.12–14 This procedure is
known as cardiopulmonary exercise testing (CPET).15–17
The principal outcome variable is maximal or peak oxygen
VO2 (VO2max or VO2peak). Historically, VO2max is used
when the measurement methodology includes determina-
tion of a plateau in VO2 measurement values during the
last work rate. In clinical practice of HF, the VO2peak is mea-
sured as the highest VO2 value, expressed as millilitres of
oxygen per kilogram of body weight per minute (mLO2
kg1min1) during the exercise test.18 Recent reports from
the Heart Failure Association of the European Society of
Cardiology (ESC)19 provides a stratification approach for di-
agnosis and prognosis of patients with HF.20 The key CPET
measurements, all clearly defined in the report, included
in the stratification are the slope of minute ventilation (VE)
relative to carbon dioxide production (VCO2; VE/VCO2
slope); peak VO2; exercise oscillatory ventilation; and the
change in the partial pressure of carbon.21–24 The stratifica-
tion also includes consideration of the blood pressure
and electrocardiographic response during the exercise
test.25–27
Today CPET is used in broader patient populations, in-
cluding women, the elderly, patients with comorbidities,
those with preserved ejection fraction, or left ventricular
assistance device recipients, i.e. individuals with different
responses to incremental exercise and markedly different
prognosis.28–30 In addition, the diagnostic and prognostic
utility of symptom-limited CPET parameters derived from
submaximal tests has been studied more and more re-
cently, for the reason that many patients are unable to
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achieve maximal aerobic power.31–33 Repeated tests are
also being used for risk stratification and evaluation of
interventions, so that more evaluative data are now avail-
able. Finally, patients, physicians, and healthcare decision
makers are increasingly considering how treatments might
impact morbidity and quality of life rather than focusing
more exclusively on hard endpoints (such as mortality) as
was often the case in the past. Innovative prognostic flow-
charts, with CPET at their core, that help optimize risk
stratification and the selection of management options in
HF patients, have been developed.34
Six-minute walk test
The role of the walking test for 6min in providing useful in-
formation in patient populations with functional limita-
tions was proposed decades ago.35 Since that time, the 6-
min walk test (6MWT) has gained acceptance in the clinical
community as a feasible option to obtain an estimate of
cardiovascular functional capacity in disease-based popu-
lations known to experience exercise intolerance.36
The 6MWT is considered simple in concept in terms of
the patient directions. The ATS guidelines provide recom-
mendations for standardizing the communication with the
patient during the test.37 However, it is important to recog-
nize that the 6MWT does not accurately predict peak VO2.
Some reports have suggested that failure to achieve a cer-
tain distance, such as 300m or 450m, on the 6MWT has
prognostic value. Additionally, some have proposed that
measures other than total distance achieved, such as total
work performed or heart rate after 1min of recovery may
provide useful information from the 6MWT. However, there
are no well-accepted normative values available to inter-
pret 6MWTresults.38
The shuttle walk test (SWT) has been also proposed to
evaluate chronic disease patient populations.39 This test
requires patients to walk back and forth around two
markers on a 10-m course (each 10m¼ 1 shuttle) at a pace
dictated by audio signals recorded on a cassette tape or
CD. The speed is initially set at 0.5m/s and increased by
0.17m/s every minute. The test is terminated when the
patient cannot complete a shuttle in the required time in-
terval. As with the 6MWT, it is recommended that only
standardized comments (no encouragement) be provided
and that the SWT is repeated at least twice to account for a
learning effect.
Other walking tests have been proposed, i.e. a 100-m
walk test in patients with pulmonary disease, 200-m fast
walking in patients in cardiac rehabilitation, and a 400-m
walk test in patients with HF: however their prognostic
powers still need to be documented.40
Table 1 summarizes the key differences between CPET
vs. 6MWT.
Muscular function
One of the most frequent misconceptions of HF is that the
limitations are solely related to the heart.14,41,42 Evidence
has existed for some time that one of significant factors as-
sociated with exercise intolerance in patients with HF is
skeletal muscle deconditioning.43,44 Recent studies have
identified mechanisms underlying the weakness observed
in the skeletal muscles or patients with HF.45,46
Thus, is it nowwell accepted that functional assessments
of patients with HF should include measures of muscular
performance.47 The gold standardmethod to assess muscu-
lar strength is the 1repetition maximum test (1RM).
The resistance for the lifting can be either free weights or
resistance exercisemachines.
Although a 1RM can be obtained from any weight lifting
exercise, the two most common lifts are the bench press
(for upper body strength) and the leg press (for lower body
strength). Unfortunately, there are no definitive standards
for interpreting 1RM performance in patients with HF.
One of the major issues with performing 1RM assessments
is the time requirement, especially if patients need to be
familiarized with using the freeweights ormachines.
A second option for performingmuscular function assess-
ments is to use a handgrip dynamometer. The procedure is
simple, only requiring the patient to squeeze the handle of
the dynamometer as hard as they can for 3 s. After a short
rest, the test is repeated two more times, with each hand
being tested. Although normative values specific for
patients with HF do not exist, large population standards
are available. These tests are starting to be administered
in the HF population.48
There are also indirect measures of muscular strength
that can be used as indicators of muscular functional abil-
ity.49–51 The origins for many of these evaluations came
from work with geriatric populations. The method that
seems to be gaining the most acceptance is the Short
Physical Performance Battery (SPPB).52
Questionnaires
Questionnaires have been proposed.53,54 Myers et al. eval-
uated the Duke Activity Status Index, the Kansas City
Cardiomyopathy Questionnaire, and the Veterans Specific
Activity Questionnaire, with results from CPET and the
6MWT: these different methods did not correlate well
with each other and concluded that they should not be
used as surrogate indicators of functional status in this
population.55,56
Conflict of interest: none declared.
Table 1 Comparative features of CPETand 6MWT
6-min walk test CPET
Exercise level Submaximal Maximal
Reproducibility þ þþþ
Availability/cost þþþ þ
Patient acceptance þþþ þ
Clinical results þ þþþ
Prognostic value þþ þþþ
Patient application Older/frail Transplant/VAD list
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